The U.S. Food and Drug Administration approved Shionogi & Co.’s ensitrelvir fumaric acid (brand name Xocova) on June 1, 2026, marking a historic regulatory milestone in COVID-19 pharmacology. The oral 3-chymotrypsin-like protease (3CLpro) inhibitor is now the first and only oral antiviral medicine approved specifically for post-exposure prophylaxis of COVID-19, indicated for adults and adolescents aged 12 years and older who have had close contact with a SARS-CoV-2-infected individual.

The approval came ahead of its Prescription Drug User Fee Act (PDUFA) action date of June 16, underscoring the priority the agency placed on this novel application. Unlike existing oral antivirals for COVID-19 — which are initiated after symptom onset — Xocova addresses an earlier, preventative use case, analogous to post-exposure prophylaxis regimens used in HIV medicine.

The regulatory decision rests on data from SCORPIO-PEP, a randomised, double-blind, placebo-controlled Phase 3 study that enrolled uninfected household contacts of confirmed COVID-19 cases. Xocova reduced the risk of symptomatic COVID-19 through Day 10 by 67% compared with placebo. The five-day oral regimen calls for three tablets on day one, followed by one tablet on days two through five — a dosing schedule that differs from its therapeutic use.

The 3CLpro mechanism of action blocks viral replication by interfering with the proteolytic processing of polyproteins translated from the viral RNA. Ensitrelvir demonstrated broad-spectrum activity against SARS-CoV-2 variants in pre-clinical studies, a property that may be critical as the virus continues to evolve.

Xocova was already approved in Japan in November 2022 under an emergency authorisation framework, providing Shionogi with real-world safety data ahead of the U.S. submission. The FDA review programme benefited from that accumulated experience, which spanned hundreds of thousands of patients in the Japanese healthcare system.

The commercial implications are significant. Post-exposure antiviral prophylaxis represents an untapped market segment, with no comparable oral agent currently approved. Shionogi estimates the total addressable population includes tens of millions of individuals globally who are exposed to COVID-19 annually but prefer to avoid infection proactively, particularly the immunocompromised, elderly, and those at heightened risk of severe disease.

Critics have noted that defining SCORPIO-PEP’s “Day 10” primary endpoint narrowly limits interpretation of long-term benefit. Shionogi will be required to conduct post-marketing studies. Still, the approval establishes a new category in antiviral drug development, and analysts expect competing programmes targeting similar prophylactic indications to intensify.